Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report

Peng,Sujuan; Huang,Hongxiang; Zhu,Xie; Chen,Jinhong; Ding,Xinjing; Wang,Fen; Chen,Li; Lu,Zhihui

doi:10.3892/etm.2024.12466

Anlotinib plus tislelizumab for recurrent metastatic pancreas ductal adenocarcinoma with germline BRCA2 mutation: A case report

Authors:
- Sujuan Peng
- Hongxiang Huang
- Xie Zhu
- Jinhong Chen
- Xinjing Ding
- Fen Wang
- Li Chen
- Zhihui Lu
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China
Published online on: March 1, 2024 https://doi.org/10.3892/etm.2024.12466
Article Number: 178
Copyright: © Peng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

While combined immunotherapy and anti-angiogenic therapy have demonstrated efficacy in renal cell carcinoma, non‑small cell lung cancer and hepatocellular carcinoma, the efficacy of first‑line treatment for pancreatic ductal adenocarcinoma (PDAC) with germline BRCA2 mutation remains unproven. We described a BRCA2‑mutated patient with PDAC who presented with posterior cardiac metastasis 8 months after surgery. After receiving four cycles of anlotinib combined with tislelizumab, abdominal CT scans indicated a complete response. The patient sustained this response for over 14 months on the combination regimen, with no reported adverse events. In conclusion, the combination of tislelizumab and anlotinib may offer a viable therapeutic option for recurrent metastatic BRCA2‑mutated PDAC.

View Figures

View References

1	Park W, Chawla A and O'Reilly EM: Pancreatic cancer: A review. JAMA. 326:851–862. 2021.PubMed/NCBI View Article : Google Scholar
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI View Article : Google Scholar
3	Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, Creemers GM, van Dam RM, et al: Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: Results of the dutch randomized phase III PREOPANC trial. J Clin Oncol. 38:1763–1773. 2020.PubMed/NCBI View Article : Google Scholar
4	Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 618:144–150. 2023.PubMed/NCBI View Article : Google Scholar
5	O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, et al: Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 38:1378–1388. 2020.PubMed/NCBI View Article : Google Scholar
6	Lai E, Ziranu P, Spanu D, Dubois M, Pretta A, Tolu S, Camera S, Liscia N, Mariani S, Persano M, et al: BRCA-mutant pancreatic ductal adenocarcinoma. Br J Cancer. 125:1321–1332. 2021.PubMed/NCBI View Article : Google Scholar
7	Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES and Reiss KA: Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Br J Cancer. 122:333–339. 2020.PubMed/NCBI View Article : Google Scholar
8	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.PubMed/NCBI View Article : Google Scholar
9	Reiss KA, Mick R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Cowden S, Southwell T, Romeo J, Izgur N, et al: Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2. J Clin Oncol. 39:2497–2505. 2021.PubMed/NCBI View Article : Google Scholar
10	Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, et al: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 381:317–327. 2019.PubMed/NCBI View Article : Google Scholar
11	Samstein RM, Krishna C, Ma X, Pei X, Lee KW, Makarov V, Kuo F, Chung J, Srivastava RM, Purohit TA, et al: Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. Nat Cancer. 1:1188–1203. 2021.PubMed/NCBI View Article : Google Scholar
12	Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB and Hosein PJ: Ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 8:1–3. 2022.PubMed/NCBI View Article : Google Scholar
13	Huang H, Zhong P, Zhu X, Fu S, Li S, Peng S, Liu Y, Lu Z and Chen L: Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC. Front Oncol. 13(1137224)2023.PubMed/NCBI View Article : Google Scholar
14	Hack SP, Zhu AX and Wang Y: Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: Challenges and opportunities. Front Immunol. 11(598877)2020.PubMed/NCBI View Article : Google Scholar
15	Wang Y, Wang B, Xiang L, Deng J, Xu B, He P, Pu W, Wang H, Fan Y and Chen H: Case report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review. Front Immunol. 13(1016647)2022.PubMed/NCBI View Article : Google Scholar
16	Mafei K, Shengyuan X and Jieqiong S: Pembrolizumab enhances the anti-pancreatic cancer activity of anlotinib. Asian J Surg. 45:881–882. 2022.PubMed/NCBI View Article : Google Scholar
17	Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, Jones O, Palmer DH, Cox TF, Smith CJ, et al: The Impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 269:520–529. 2019.PubMed/NCBI View Article : Google Scholar
18	Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ and Anthoney A: Redefining the R1 resection in pancreatic cancer. Br J Surg. 93:1232–1237. 2006.PubMed/NCBI View Article : Google Scholar
19	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982.PubMed/NCBI
20	NCCN Guidelines Panel Disclosures. NCCN Clinical Practice Guidelines in Oncology-Pancreatic Adenocarcinoma (Version 2.2023). [June 19, 2023]. https://www.nccn.org/patientresources/patient-resources/guidelines-for-patients.
21	Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, Coxon F, Ross P, Madhusudan S, Roques T, et al: Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomised, phase 3 trial. Lancet Oncol. 15:829–840. 2014.PubMed/NCBI View Article : Google Scholar
22	Lellouche L, Palmieri LJ, Dermine S, Brezault C, Chaussade S and Coriat R: Systemic therapy in metastatic pancreatic adenocarcinoma: Current practice and perspectives. Ther Adv Med Oncol. 13(17588359211018539)2021.PubMed/NCBI View Article : Google Scholar
23	Walsh CS: Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy. Gynecol Oncol. 137:343–350. 2015.PubMed/NCBI View Article : Google Scholar
24	Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, et al: Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673. Cancer Lett. 364:8–16. 2015.PubMed/NCBI View Article : Google Scholar
25	Wang Y, Park JYP, Pacis A, Denroche RE, Jang GH, Zhang A, Cuggia A, Domecq C, Monlong J, Raitses-Gurevich M, et al: A preclinical trial and molecularly annotated patient cohort identify predictive biomarkers in homologous recombination-deficient pancreatic cancer. Clin Cancer Res. 26:5462–5476. 2020.PubMed/NCBI View Article : Google Scholar
26	Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the national cancer institute of canada clinical trials group. J Clin Oncol. 25:1960–1966. 2007.PubMed/NCBI View Article : Google Scholar
27	Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 22:1430–1438. 2004.PubMed/NCBI View Article : Google Scholar
28	Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W, Shang A, Cosaert J and Moore MJ: Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 27:2231–2237. 2009.PubMed/NCBI View Article : Google Scholar
29	Kindler HL, Niedzwiecki D, Hollis D, Sutherland S, Schrag D, Hurwitz H, Innocenti F, Mulcahy MF, O'Reilly E, Wozniak TF, et al: Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: Phase III trial of the cancer and leukemia group B (CALGB 80303). J Clin Oncol. 28:3617–3622. 2010.PubMed/NCBI View Article : Google Scholar
30	Kindler HL, Ioka T, Richel DJ, Bennouna J, Létourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol. 12:256–262. 2011.PubMed/NCBI View Article : Google Scholar
31	Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, et al: BAYPAN study: A double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 23:2799–2805. 2012.PubMed/NCBI View Article : Google Scholar
32	Rougier P, Riess H, Manges R, Karasek P, Humblet Y, Barone C, Santoro A, Assadourian S, Hatteville L and Philip PA: Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer. Eur J Cancer. 49:2633–2642. 2013.PubMed/NCBI View Article : Google Scholar
33	Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, et al: Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC study. Cancer Sci. 106:883–890. 2015.PubMed/NCBI View Article : Google Scholar
34	Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM, et al: CONKO-005: Adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: A multicenter randomized phase III trial. J Clin Oncol. 35:3330–3337. 2017.PubMed/NCBI View Article : Google Scholar
35	Sun Y, Niu W, Du F, Du C, Li S, Wang J, Li L, Wang F, Hao Y, Li C and Chi Y: Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 9(105)2016.PubMed/NCBI View Article : Google Scholar
36	Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
37	Wu H, Huang N, Zhao C, Hu X, Da L, Huang W, Shen Y, Xiong F and Zhang C: Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: A retrospective cohort. Ann Transl Med. 10(294)2022.PubMed/NCBI View Article : Google Scholar
38	Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R and Zhao J: Anlotinib: A novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 11(120)2018.PubMed/NCBI View Article : Google Scholar
39	Yang L, Zhou X, Sun J, Lei Q, Wang Q, Pan D, Ding M and Ding Y: Reactive oxygen species mediate anlotinib-induced apoptosis via activation of endoplasmic reticulum stress in pancreatic cancer. Cell Death Dis. 11(766)2020.PubMed/NCBI View Article : Google Scholar
40	Zhang X, Liu Y, Zhang Z, Tan J, Zhang J, Ou H, Li J and Song Z: Multi-omics analysis of anlotinib in pancreatic cancer and development of an anlotinib-related prognostic signature. Front Cell Dev Biol. 9(649265)2021.PubMed/NCBI View Article : Google Scholar
41	Timmer FEF, Geboers B, Nieuwenhuizen S, Dijkstra M, Schouten EAC, Puijk RS, de Vries JJJ, van den Tol MP, Bruynzeel AME, Streppel MM, et al: Pancreatic cancer and immunotherapy: A clinical overview. Cancers (Basel). 13(4138)2021.PubMed/NCBI View Article : Google Scholar
42	Zhang F, Wang Y, Yang F, Zhang Y, Jiang M and Zhang X: The efficacy and safety of PD-1 inhibitors combined with nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine in the first-line treatment of advanced pancreatic cancer: A retrospective monocentric study. Cancer Manag Res. 14:535–546. 2022.PubMed/NCBI View Article : Google Scholar
43	Shui L, Cheng K, Li X, Shui P, Zhou X, Li J, Yi C and Cao D: Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma. BMC Cancer. 20(636)2020.PubMed/NCBI View Article : Google Scholar
44	Liu Q, Zhao G, Zhang X, Jiang N, Zhao Z, Wang Y, Xu S, Zhu L, Lau WY, Dai G and Liu R: Nab-paclitaxel plus S-1 with or without PD-1 inhibitor in pancreatic ductal adenocarcinoma with only hepatic metastases: A retrospective cohort study. Langenbecks Arch Surg. 407:633–643. 2022.PubMed/NCBI View Article : Google Scholar
45	Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, et al: Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 38:1–10. 2020.PubMed/NCBI View Article : Google Scholar
46	Padrón LJ, Maurer DM, O'Hara MH, O'Reilly EM, Wolff RA, Wainberg ZA, Ko AH, Fisher G, Rahma O, Lyman JP, et al: Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: Clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat Med. 28:1167–1177. 2022.PubMed/NCBI View Article : Google Scholar
47	Feng M, Xiong G, Cao Z, Yang G, Zheng S, Song X, You L, Zheng L, Zhang T and Zhao Y: PD-1/PD-L1 and immunotherapy for pancreatic cancer. Cancer Lett. 407:57–65. 2017.PubMed/NCBI View Article : Google Scholar
48	Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I and Rosenberg SA: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 33:828–833. 2010.PubMed/NCBI View Article : Google Scholar
49	O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, et al: Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial. JAMA Oncol. 5:1431–1438. 2019.PubMed/NCBI View Article : Google Scholar
50	Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017.PubMed/NCBI View Article : Google Scholar
51	Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019.PubMed/NCBI View Article : Google Scholar
52	Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.PubMed/NCBI View Article : Google Scholar
53	Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.PubMed/NCBI View Article : Google Scholar
54	Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020.PubMed/NCBI View Article : Google Scholar
55	Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718. 2019.PubMed/NCBI View Article : Google Scholar
56	Li SQ, Yang Y and Ye LS: Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. World J Gastroenterol. 28:6034–6044. 2022.PubMed/NCBI View Article : Google Scholar
57	Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F and Abbruzzese JL: Evidence for the efficacy of iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 31:1417–1420. 2011.PubMed/NCBI
58	Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, et al: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 33:244–250. 2015.PubMed/NCBI View Article : Google Scholar
59	Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M and O'Neil BH: Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic adenocarcinoma patients treated with FOLFIRINOX. Clin Cancer Res. 24:6204–6211. 2018.PubMed/NCBI View Article : Google Scholar
60	Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E and Ghiringhelli F: Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment. BMC Cancer. 20(748)2020.PubMed/NCBI View Article : Google Scholar